Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
New York City
Friday, October 4 at 7:45 a.m. Eastern time (ET).
April 5, 2016
Geneva, Switzerland, 05 April, 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced that Ernest Loumaye,…Read more
March 24, 2016
Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…Read more
November 23, 2015
Geneva, Switzerland, 23 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising…Read more
May 8, 2019
May 9, 2018
March 2, 2020
November 11, 2019
October 17, 2019